Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending November 22, 2015
Cognitive Decline in Multiple Sclerosis, Assessing the effects of thalamus atrophy
Detecting Autoantibodies in Multiple Sclerosis, Evaluating the use of electrochemiluminescence assay
Cerebellar Growth in CNS Demyelinating Disease, Does age of onset correlate with volume loss?
Teriflunomide in Relapsing-Remitting MS, Comparing adverse events across studies
Escalation of Therapy in Neuromyelitis Optica Attacks, Do multiple courses of treatment affect outcomes?
Must reads for theWeek ending November 15, 2015
HRQOL Following Minor Ischemic Events, Predicting impairment at 3 months
Neurofilament Light Concentration in Alzheimer Disease, Studying associations with cognitive deterioration
Cerebral Amyloid Angiopathy in AD, Defining cognitive associations
Narcolepsy in African Americans, Does ethnicity affect sleep patterns?
Curative Surgery for Epileptic Spasms, Which procedures produce the best outcomes?
Must reads for theWeek ending November 8, 2015
Progressive Multifocal Leukoencephalopathy in MS, Evaluating the role of John Cunningham virus
Soluble CD26 and CD30 in MS, Assessing associations with immune responses
Alemtuzumab in Relapsing MS, Does clinical trial data hold up?
Cardiac Events in Fingolimod Initiation, Evaluating events in 850 episodes
Associations Between Symptoms, Community Integration, and Mental Health, Does MS type or level of progression define the patient?
Must reads for theWeek ending November 1, 2015
Mild Traumatic Brain Injury and PTSD, Does it have prognostic value?
Brivaracetam and Partial-Onset Seizures, Studying efficacy and tolerance
PTSD in Patients With Migraine, Assessing the impact
Sleep Apnea and Cardiovascular Surgery, Does it affect outcomes?
Imaging Assessments vs Outcomes in Stroke, Evaluating mismatch profiles
Must reads for theWeek ending October 25, 2015
Oligoclonal Bands and Multiple Sclerosis, Assessing their significance in patients with CIS
Cladribine in Multiple Sclerosis, Does it confer cancer risk?
MOG-Ab in Inflammatory Demyelinating Disease, Evaluating its utility as biomarker
Vitamin D and Multiple Sclerosis, Studying associations with regulatory variants
Statins in RRMS Therapy, Is there benefit to their addition?